Marken launches kit building facility for clinical trials in Asia Pacific

By Flora Southey contact

- Last updated on GMT

Marken has opened a facility in China where it will assemble kits used to collect biological samples from patients in trials.

The 370m² facility – located in the Pudong district of Shanghai – houses a processing area to assemble kits, a temperature-controlled storage area, and office space.

Marken said the site can produce up to 100,000 kits per month, and will deliver sampling kits to all of Marken’s pharmaceutical depots and investigator sites when necessary.

Existing clients will benefit from the Shanghai facility, Marken’s Christine Noble told us: “Being centrally located within the Pudong district provides easy access to the Pudong International Airport for client shipments.”

“The combined centrally-located facility will enhance the ability to import raw materials for the kits and to also distribute kits domestically throughout China,” ​she added.

Increased demand?

Marken will continue to ship biological samples to laboratories and clinical drug products, driven by the increased number of clinical trials taking place across Asia Pacific countries, Noble told us.

Marken is meeting this increased demand by providing sites located as close to the patient as possible, she said: “Having a kit building facility in China, alongside Marken’s 13 other APAC [Asia Pacific] locations, provides the ability for Marken to distribute kits on behalf of our clients throughout all of China and the Asia Pacific region as a whole.​ 

“Clients tell us they expect a continuing increase in the number of trials in that part of the world, and they also recognise that choosing a strong supply chain partner can reduce risk and potential temperature excursions for biological samples and clinical drug products,” ​she told us.

The facility is Marken’s third kit building site, along with Hamburg and Singapore locations.

Last month, Marken announced​ plans open a new branch in Ahmedabad, India.

Earlier last year, the supply chain organisation – which was bought​ by UPS in 2016 – launched​ a new hybrid logistics service using UPS’ airport, pilot, and aeroplane transportation network.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more